Download Library

Document Type

Corporate Presentation

Corporate Presentation

2017 Proxy Statement

2016 Annual Report

View Presentation

View Presentation

View Presentation

View Presentation

Two Phase 3 studies of the efficacy and safety of AR13324 Ophthalmic Solution 0.02%: in Patients with Open Angle Glaucoma and Ocular Hypertension

The mechanisms of increasing outflow facility by AR13324M in human eyes